A phase I study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, for intravenous (IV) administration in patients with advanced solid tumors. (December 2016) - Razak, A.; Gore, L.; Britten, C.D.; Miller, W.H.; Uy, G.L.; Nichols, G.; Middleton, S.; Blotner, S.; Zhi, J.; Jukofsky, L.; Pierceall, W.; Higgins, B.; et al.